Discovery of novel broad-spectrum coronavirus inhibitors

新型广谱冠状病毒抑制剂的发现

基本信息

批准号：
10514153
负责人：
VINEET D MENACHERY
金额：
$ 288.9万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514153
关键词：
2019-nCoV Achievement Active Immunization Address Animal Model Animals Antiviral Agents Biochemical Biological Biological Assay Biology Biophysics COVID-19 vaccine Cells Chemicals Civilization Clinical Trials Coronavirus Dengue Virus Development Disease Disease Outbreaks Engineering Epidemic Family Flavivirus Future Goals Hamsters Henipavirus Human In Vitro Infection Interruption Lead Libraries Life Life Cycle Stages Medicine Middle East Respiratory Syndrome Coronavirus Modeling Morbidity - disease rate Mus Mutation Oral Outcome Passive Immunization Peptide Hydrolases Pharmaceutical Chemistry Polymerase Predisposition Process Property Proteins Recombinant Proteins Recombinants Recording of previous events Reporter Resistance SARS coronavirus Structure System Testing Therapeutic Toxicology Triage Viral Viremia Virus Virus Inhibitors Virus Replication Work airway epithelium base biosafety level 2 facility coronavirus antiviral coronavirus therapeutics drug candidate experience fitness human coronavirus human disease in vivo in vivo Model inhibitor intravenous injection mortality mutant novel novel therapeutics pandemic preparedness pathogen population health preclinical development prevent remdesivir resistance mutation screening small molecule therapeutic target tool

项目摘要

PROJECT 2 – ABSTRACT The goal of this project is to discover novel broad-spectrum coronavirus inhibitors. We will identify new broad- spectrum coronavirus inhibitors of viral replication using a cell-based approach. We will achieve the goal by pursuing three aims. (i) Screen and identify novel compounds for broad-spectrum coronavirus inhibition. We will screen and identify inhibitors of viral replication using SARS-CoV-2, MERS-CoV, and 229E infection assays. UTMB has developed an single-cycle infection system for SARS-CoV-2 that can be used for HTS campaign at BSL2. In this application, we will expand this system to MERS-CoV. We will also develop a reporter 229E coronavirus for antiviral screen. (ii) Develop tool compounds, determine target protein, and optimize molecules. (iii) Evaluate lead compounds in relevant in vitro and in vivo models and select Development Candidate for IND- enabling studies. The proposed cell-based approach may discover novel antiviral targets that may not be tractable for target-based antiviral approach.

项目2 - 摘要该项目的目的是发现新颖的广谱冠状病毒抑制剂。我们将确定新的广泛 - 使用基于细胞的方法的病毒复制频谱冠状病毒抑制剂。我们将通过追求三个目标。（i）筛选并鉴定新的化合物，以示宽光谱冠状病毒抑制作用。我们将使用SARS-COV-2，MERS-COV和229E感染测定法进行筛选并鉴定病毒复制的抑制剂。 UTMB已开发了一种用于SARS-COV-2的单周期感染系统，可用于HTS活动。 BSL2。在此应用程序中，我们将将此系统扩展到MERS-COV。我们还将开发一个记者229E 抗病毒筛查的冠状病毒。（ii）开发工具化合物，确定靶蛋白并优化分子。（iii）评估相关体外和体内模型中的铅化合物，并选择索引的发展候选者启用研究。提出的基于细胞的方法可能会发现可能不是的新型抗病毒靶标可用于基于目标的抗病毒方法。